BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 35641856)

  • 1. Endometrial Cancer Following Levonorgestrel-Releasing Intrauterine System Insertion in Young Women with Atypical Hyperplasia: Two Case Reports and Literature Review.
    Peng H; Jiang J; Li X
    Reprod Sci; 2022 Nov; 29(11):3278-3284. PubMed ID: 35641856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levonorgestrel-releasing intrauterine system for endometrial hyperplasia.
    Mittermeier T; Farrant C; Wise MR
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD012658. PubMed ID: 32909630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study.
    Giampaolino P; Di Spiezio Sardo A; Mollo A; Raffone A; Travaglino A; Boccellino A; Zizolfi B; Insabato L; Zullo F; De Placido G; Bifulco G
    J Minim Invasive Gynecol; 2019; 26(4):648-656. PubMed ID: 30017893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral and intrauterine progestogens for atypical endometrial hyperplasia.
    Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia.
    Lv X; Guo L; Wang C
    J Gynecol Oncol; 2024 May; 35(3):e27. PubMed ID: 38216133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced endometrial cancer following the insertion of the levonorgestrel-releasing intrauterine system in a 34-year-old woman: A case report.
    Jiang J; Du H; Peng H
    Contraception; 2020 Dec; 102(6):428-429. PubMed ID: 32860769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestin receptor isoforms and prostaglandin dehydrogenase in the endometrium of women using a levonorgestrel-releasing intrauterine system.
    Critchley HO; Wang H; Kelly RW; Gebbie AE; Glasier AF
    Hum Reprod; 1998 May; 13(5):1210-7. PubMed ID: 9647549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Romero SA; Young K; Hickey M; Su HI
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study.
    Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study.
    Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB
    Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Dominick S; Hickey M; Chin J; Su HI
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen.
    Chin J; Konje JC; Hickey M
    Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levonorgestrel-releasing intrauterine device plus metformin, or megestrol acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and early endometrial carcinoma: a prospective, randomized, blind-endpoint design trial protocol.
    Zhao X; Niu J; Shi C; Liu Z
    Reprod Health; 2022 Nov; 19(1):206. PubMed ID: 36333773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of levonorgestrel-releasing intrauterine device in the treatment of atypical endometrial hyperplasia and early endometrial cancer.
    Hirata T; Kondo E; Magawa S; Kubo-Kaneda M; Nii M; Yoshida K; Maezawa T; Tabata T; Ikeda T
    J Obstet Gynaecol Res; 2022 Dec; 48(12):3219-3225. PubMed ID: 36054237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia.
    Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM
    J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
    Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P
    Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review.
    Buttini MJ; Jordan SJ; Webb PM
    Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):316-22. PubMed ID: 19566568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer.
    Westin SN; Fellman B; Sun CC; Broaddus RR; Woodall ML; Pal N; Urbauer DL; Ramondetta LM; Schmeler KM; Soliman PT; Fleming ND; Burzawa JK; Nick AM; Milbourne AM; Yuan Y; Lu KH; Bodurka DC; Coleman RL; Yates MS
    Am J Obstet Gynecol; 2021 Feb; 224(2):191.e1-191.e15. PubMed ID: 32805208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and fertility outcomes of levonorgestrel-releasing intra-uterine system treatment for patients with atypical complex hyperplasia or endometrial cancer: a retrospective study.
    Leone Roberti Maggiore U; Martinelli F; Dondi G; Bogani G; Chiappa V; Evangelista MT; Liberale V; Ditto A; Ferrero S; Raspagliesi F
    J Gynecol Oncol; 2019 Jul; 30(4):e57. PubMed ID: 31074240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.